Calidi Biotherapeutics Inc (CLDI) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Calidi Biotherapeutics Inc   (NYSEAMER: CLDI)


Calidi Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Calidi Biotherapeutics Inc's ROI in the second quarter of 2026?
Calidi Biotherapeutics Inc recorded a cumulative net loss of $-18 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -294.75%.

Within the Healthcare sector 510 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3639 to 4282.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 58.52 % 493.96 % - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 4 6 5 9 4
Return On Investment (TTM) -294.75 % -317.12 % -283.14 % -259 % -490.2 %
CLDI's Overall Ranking # 4282 # 3639 # 3725 # 4076 # 3865
Seq. Investment Change TTM -1.42 % -14.96 % -0.69 % 90.42 % 269.37 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -18 -19 -20 -18 -18




Return On Investment CLDI's Ranking
Within: No.
Industry # 80
Sector # 511
Overall # 4282

Return On Investment Statistics
High Average Low
3.78 %
-280.13 %
-1975.95 %
(Sep 30 2022)   (Mar 31 2025)







Financial Statements
Calidi Biotherapeutics Inc's II. Quarter Investments $ 4 Millions CLDI's Balance sheet
Calidi Biotherapeutics Inc's II. Quarter Income $ -4 Millions Quarterly CLDI's Income Statement
CLDI's Income by Division See CLDI's Income by Division


CLDI Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 5 5 0 38 223
Y / Y Investment Growth -3.87 % - - -82.95 % -
Net Income in Millions -20 -22 -29 4 3
Y / Y Net Income Growth - - - 4.24 % -
Annual Return On Investment -407.62 % -433.77 % - 9.29 % 1.52 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CLDI's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CLDI's Competitors
Subscribers only: Roi for Calidi Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for CLDI's Customers

Other Ratios
CLDI's Roa CLDI's Inventory Turnover Ratio CLDI's Growth Rates CLDI's Dividend Statistics
CLDI's Profitability Ratios CLDI's Asset Turnover Ratio CLDI's Dividend Growth
CLDI's Roe CLDI's Valuation Ratios CLDI's Financial Strength Ratios CLDI's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-02T20:40:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.